Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation
1985

5-Day Regional Chemotherapy with 5-Fluorouracil for Colon Cancer

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): J.-Louis Boublil, G. Milano, R. Khater, J. Bourry, A. Thyss, J.-N. Bruneton, N. Renee, C. Philip, M. Namer

Primary Institution: Centre Antoine Lacassagne

Hypothesis

How do different routes of administering 5-fluorouracil affect its pharmacokinetics in patients with colon carcinoma?

Conclusion

The intra-arterial hepatic and portal vein routes significantly improve drug delivery compared to the intra-arterial pelvic route.

Supporting Evidence

  • 5-FU blood levels were measured every day for a total of 87 cycles.
  • Both the i.a.h. and i.p.v. routes resulted in significant reductions in drug levels compared to the i.v. route.
  • Increasing the dose led to a modification in circulating 5-FU levels proportional to the dose for the i.v. and i.a.p. routes.
  • For the i.a.h. and i.p.v. routes, systemic drug delivery was significantly elevated, indicating a saturable process.
  • Local extraction for the i.a.p. route was non-existent, showing no advantage over classical i.v. infusion.

Takeaway

Doctors gave a medicine called 5-FU to 18 patients in different ways to see which way worked best. They found that some ways helped the medicine work better.

Methodology

Patients received continuous 5-day infusions of 5-FU through different routes, and blood levels were measured daily.

Limitations

The small number of patients in the intra-arterial pelvic group limits the generalizability of the results.

Participant Demographics

18 patients (13 male, 5 female) with a mean age of 65 years.

Statistical Information

P-Value

P<0.001

Confidence Interval

(0.90-0.95)

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication